FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Name and Address of Reporting Person* Sandrock Alfred						2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [BIIB]											all applic	cable)	g Per	son(s) to Iss 10% Ov Other (s	wner	
(Last) BIOGEN 225 BIN		3. Date of Earliest Transaction (Month/Day/Year) 02/08/2016											EVP CMO Neuro & Neurodegenerat									
(Street) CAMBR (City)			02142 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)										Indiv ne) X	,					
		Tab	le I - No	n-Deriv	ative	Sec	curit	ies Ac	cqui	ired,	Dis	posed c	of, o	r Ber	neficia	ally (Owned	I				
Date				Date				2A. Deemed Execution Date, if any (Month/Day/Year)			ction nstr.	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				4 and 5) Securit Benefic Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
										Code	v	Amount		(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock				02/08/	02/08/2016				\top	М		1,278		A	\$0		9,018		D			
Common Stock 02/0					/2016	2016				F		426		D	\$250.		7 8,592		D			
Common Stock 02/0					/2016					S ⁽¹⁾		852		D \$24		.54	7,740		D			
		7	able II -									osed of					wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Executior if any (Month/Da	n Date,	4. Transa Code (i 8)		n of		Exp	Date Expiration onth/Da	Date		7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		Security	De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exe	te ercisabl		Expiration Date	Title		Amount or Number of Shares							
Restricted	\$0	02/08/2016		T	м	1 278			(2)		02/08/2016	Cor	mmon	1 278		\$0	0		D			

Explanation of Responses:

- 1. Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- 2. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).

Matthew S. Gilman, Attorney in Fact for Alfred W. Sandrock, 02/10/2016 Jr.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.